Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 13 Sept 2013 |
| Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma | 10 Sept 2013 |
| Genmab's Total Number of Voting Rights and Total Share Capital | 30 Aug 2013 |
| Genmab Reaches Milestone in DuoBody Platform Collaboration with Janssen | 26 Aug 2013 |
| Articles of Association for Genmab A/S | 22 Aug 2013 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 21 Aug 2013 |